BeyondSpring Inc (BYSI)

2.640 +0.140 (+5.60%)
Closed USD Disclaimer
2.710 +0.070 (+2.652%)

BeyondSpring Inc Company Profile

Equity Type
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company’s lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.
Contact Information
West Side Florham Park,07932 United States
(646) 305-6387
Top Executives
Patrick Fabbio 56 2018 Independent Director
Yan Sun 0 0000 Member of Scientific Advisors & Principal Investigators Board
Douglas W. Blayney 74 0000 Member of Scientific Advisors & Principal Investigators Board
Yuankai Shi 0 0000 Member of Scientific Advisors & Principal Investigators Board
Matthew Kirkby 55 2016 Independent Director
David S. Ettinger 0 0000 Member of Scientific Advisors & Principal Investigators Board
Jeffrey Crawford 0 0000 Member of Scientific Advisors & Principal Investigators Board
Lan Huang 53 2014 Co-Founder, Chairman & CEO
Jiangwen Majeti 56 2022 Independent Director
Brendan P. Delaney 49 2021 Independent Director
Sihai Xu 52 2022 Director
Clear All
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.